EUVIMEDEUVIMED entdecken
Crossref

Getting the Rug Pulled Out From Under You

Daniel M Geynisman

Journal of the National Comprehensive Cancer Network · 2026-07 · 24 (7)

DOI: 10.6004/jnccn.2026.0035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-07. Verfasst von Daniel M Geynisman. Die Arbeit nennt 2 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Getting the Rug Pulled Out From Under YouA t the recent 2026 annual ASCO meeting, one of the plenary session presentations was of a trial called PROTEUS. 1 This global phase III trial involved more than 2,000 men with high-risk prostate cancer undergoing prostatectomy, who were randomized to receive perioperative androgen deprivation therapy (ADT) or ADT with an androgen receptor inhibitor, apalutamide.The results showed improvements in metastasis-free survival and several other clinical endpoints, such as the use of subsequent systemic therapy and event-free survival.Given the meaningful impact on patient outcomes, apalutamide may, as the discussants and editorial writers in multiple outlets suggested, become a new option, if not a standard of care, for men with high-risk prostate cancer who choose to undergo surgery.But that brings up the question: an option or standard of care where?I suspect in few places in the world.The trial was conducted in 18 countries on multiple continents, but like many phase II and III international trials of novel medicines, the drug may ultimately only achieve regulatory approval and be widely accessible in some of those countries.A recent study by Lee et al 2 underscored this point.The investigators looked at 172 novel medications approved by the FDA from 2015 to 2018 that were evaluated in 89 countries via 885 clinical trials.Of the 144 medications tested outside the United States, only 24% were accessible in all countries where they were studied at 5 years after FDA approval.Not surprisingly, middle and lower-income countries (LMICs) had less access than high-income countries, but even in the latter, where 142 of the 144 drugs were tested, only 45 were eventually available.Access has improved over time in Western countries but not in LMICs.In other words, patients and citizens of a given country participate in a global trial, their participation yields a positive result, and the drug gets approved in the United States and some other countries, but in many countries where the trial was conducted, for a variety of reasons, patients will not have access to it.This is not breaking news, and this situation has been going on for a long time, but this massive global trial reminded me of the inequity of access.As Lee et al 2 suggest (and I agree), "Most countries participating in trials for FDA approvals cannot physically access the medicines they test, particularly LMICs, raising exploitation concerns."One can certainly argue that the trial benefited at least some patients in those countries, who otherwise would not have had any access to the new drug.Still, this seems like a very low bar.Solutions are difficult, of course, but I would advocate that the oncology community take an organized approach to addressing the barriers that keep progress from reaching the intended audience in a timely manner.While these efforts need support from pharmaceutical industry leaders, advocacy groups and policymakers, even raising awareness of the issues as oncologists could accelerate progress.One way in which we can impact access is by using evidence-based guidelines and highlighting how standardizing treatment and access allows progress to occur, both with individual patients and the population affected by a given cancer.If the evidence is compelling, the drug may be incorporated into evidence-based guidelines, which can then inform coverage policymaking and capacity building.For example, the NCCN Adapted Guidelines for Sub-Saharan Africa, co-created by African experts and the American Cancer Society, enable oncologists to advocate for standardized, evidencebased cancer medicines with their governments.This effort aligns with the Union for International Cancer Control (UICC)'s ATOM (Access to Oncology Medicines) coalition, of which NCCN and ASCO are members, where internationally recognized guidelines are used to identify essential cancer medications that are then advocated for at the country level in LMICs.WHO also has an Essential Medicines List that is evidence-based to increase access.

Zitieren

APA

Geynisman, D. M. (2026). Getting the Rug Pulled Out From Under You. Journal of the National Comprehensive Cancer Network, 24(7). https://doi.org/10.6004/jnccn.2026.0035

Vancouver

Geynisman DM. Getting the Rug Pulled Out From Under You. Journal of the National Comprehensive Cancer Network. 2026;24(7). doi:10.6004/jnccn.2026.0035

BibTeX
@article{Geynisman2026,
  author = {Geynisman, Daniel M},
  title = {Getting the Rug Pulled Out From Under You},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {7},
  doi = {10.6004/jnccn.2026.0035}
}
Kostenlos starten →